Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9008959 | 0.79 | LMNA (0.49) | LMNASLC1A3SLC1A2SLC1A1MGLL | |
| SCHEMBL3230353 | 0.77 | LMNA (0.46) | LMNASLC1A3SLC1A2SLC1A1CTSL | |
| SCHEMBL21235969 | 0.77 | LMNA (0.46) | LMNASLC1A3SLC1A2SLC1A1MGLL | |
| SCHEMBL18676354 | 0.77 | LMNA (0.42) | LMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18801019 | 0.74 | LMNA (0.42) | LMNASLC1A3SLC1A2SLC1A1CTSL | |
| SCHEMBL27359823 | 0.74 | LMNA (0.43) | LMNASLC1A3SLC1A2SLC1A1CTSL | |
| SCHEMBL2369588 | 0.73 | — | — | |
| SCHEMBL8894600 | 0.73 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1MGLL | |
| SCHEMBL8895546 | 0.73 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1MGLL | |
| SCHEMBL12197855 | 0.72 | LMNA (0.42) | LMNASLC1A3SLC1A2SLC1A1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | LMNA 877/4885SLC1A3 772/4885SLC1A2 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.